Prothena Corporation plc Ordinary Shares(PRTA)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- 52-Week Range
- $7.73 – $11.80
- YTD
- -9.89%
- IV Rank (30D)
- 72.81
- Straddle Price
- $0.98
- P/C Vol Ratio
- 0.00
- Market Cap
- $0.4B
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.96% |
| Beta vs SPY | 0.87 |
| Cost of Equity (CAPM) | 9.32% (VRP-adj) |
| WACC | 9.38% |
| Volatility Risk Premium | +144.5pp (IV − HV30) |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | -10.0% |
| DCF Horizon | 10 years explicit + fade |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -15.3% |
| Book / Price | 64.5% — banking bias active (P/B is primary) |
| Gross Margin (TTM) | 100.0% |
| FCF Margin (TTM) | -111.3% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $8.89 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $9.01 |
| Bollinger Width / SMA20 | 241.7% (drives anchor stability) |
| Net Debt | $-0.3B |
| Market Cap | $0B |
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 40.3× · 3 peers |
| Peer EV/EBITDA | n/a | 0% | median 39.3× · 3 peers |
| Peer P/B | $17.97 | 50% | median 3.4× · 5 peers |
| Peer P/S | $4.12 | 50% | median 4.0× · 4 peers |
| Market Anchor (SMA50) | $8.89 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $9.30 | 0% | 8 strikes · skew -0.79 |
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
- Market Cap
- $0.4B
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, bein…
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -7.80% | 6 |
| Feb | +10.30% | 6 |
| Mar | -5.19% | 6 |
| Apr | -5.64% | 6 |
| May | -0.69% | 6 |
| Jun | +17.81% | 6 |
| Jul | +4.89% | 6 |
| Aug | +2.25% | 6 |
| Sep | +18.41% | 6 |
| Oct | -6.64% | 5 |
| Nov | -7.67% | 5 |
| Dec | +1.59% | 5 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report
Executive Summary
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers:
- Positive news sentiment from recent headlines, particularly Novo Nordisk's Coramitug study and Alpha-Synuclein Inhibitors clinical trial pipeline
- Bullish momentum signals from technical indicators, including MACD and Stochastic %K
Primary Risks:
- Negative news impact from FDA guidelines on Leqembi therapy and Prothena Corporation PLC's mid-stage Parkinson's trial missing primary endpoint
- Volatility regime indicating moderate risk relative to market
Investment Thesis: PRTA's neutral sentiment and moderate volatility suggest a potential range-bound trading environment. The stock's recent uptrend may continue, driven by positive news flows and bullish momentum signals.
Recent News Sentiment Impact: The overall sentiment is NEUTRAL, with two positive headlines and three negative/neutral headlines. This mix of sentiment does not significantly impact the analysis, as the technical indicators are more prominent in determining the current trading environment.
Technical Analysis
Trend Direction: Short-term (1-4 weeks) - UPTREND; Medium-term (1-3 months) - UPTREND; Long-term (3-12 months) - NEUTRAL
Support/Resistance Levels: Key price levels include: + Lower band: $8.71 + Middle band: $9.27 + Upper band: $9.83 + Trend line: $9.44 (EMA 26)
Momentum Signals:
- RSI interpretation: Neutral (63.37) - not overbought or oversold
- MACD signal: Bullish (0.21 / Signal: 0.06 / Histogram: 0.15)
- Bollinger Bands position: Squeeze ( price touching upper band)
Volume Analysis: Volume trends and institutional interest signals: + Volume SMA 20: 359105.03 + On-Balance Volume (OBV): -8151475.14 + Volume Rate of Change: 2.10%
News & Sentiment Analysis
Recent Headlines Summary: Positive news flows from Novo Nordisk's Coramitug study and Alpha-Synuclein Inhibitors clinical trial pipeline, while negative/neutral headlines from FDA guidelines and Prothena Corporation PLC's mid-stage Parkinson's trial missing primary endpoint.
Sentiment Assessment: Aggregate news sentiment is NEUTRAL, with a mix of positive and negative headlines.
Catalyst Identification: Upcoming events include earnings releases from Novo Nordisk and Prothena Corporation PLC. Regulatory changes and product launches may also impact the stock price.
Market Narrative: The recent uptrend in PRTA's stock price is driven by positive news flows and bullish momentum signals, which align with the technical indicators' trend direction.
Risk & Volatility Assessment
Beta Interpretation: Beta of 0.99 indicates moderate volatility relative to market (SPY).
Volatility Regime: The current regime suggests a moderate risk environment, with historical volatility levels indicating a higher-than-average level of uncertainty.
Options Market Signals: IV rank is low at 13.2%, suggesting historically low volatility. Put/call ratios indicate bullish sentiment, while unusual activity signals institutional interest in the options market.
Downside Protection: Support levels include lower band ($8.71), middle band ($9.27), and trend line ($9.44).
Market Context & Positioning
Sector Performance: PRTA's sector (Biotech) has been relatively strong, with a positive correlation to the broader market (SPY).
Institutional Activity: Institutional interest is moderate, with a volume flow of 6 calls vs 0 puts and open interest of 83 calls vs 0 puts.
Correlation Analysis: PRTA's correlation to SPY is 0.27, indicating a relatively low level of correlation.
Relative Valuation: PRTA's relative valuation suggests it is trading within its historical range, with no clear value or overvaluation signals.
Key Levels & Action Items
Critical Price Levels:
- Lower band: $8.71
- Middle band: $9.27
- Upper band: $9.83
Breakout/Breakdown Levels: Trend line ($9.44) and middle band ($9.27)
Time-Sensitive Catalysts: Upcoming earnings releases from Novo Nordisk and Prothena Corporation PLC.
Risk Management: Stop-loss levels can be set at the lower band ($8.71) or trend line ($9.44), with position sizing considerations based on risk tolerance and market conditions.
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2024-11-12 | Pre-Market | 15.49% | 3.98% | 0.26x | Within |
| 2025-05-08 | Pre-Market | 18.86% | 2.81% | 0.15x | Within |
| 2025-08-04 | Pre-Market | 30.84% | 1.91% | 0.06x | Within |
| 2025-11-06 | Pre-Market | 17.04% | 2.34% | 0.14x | Within |
| 2026-02-19 | Pre-Market | 21.42% | 0.53% | 0.02x | Within |
| 2026-05-07 | After-Close | 9.27% | 2.00% | 0.22x | Within |
| 2026-08-06 | Pre-Market | 55.95% | 3.06% | 0.05x | Within |
- IV Rank (30D)
- 72.81
- IV Rank (7D)
- 72.81
- Avg IV
- 240.6%
- Straddle (30D)
- $0.98
- Straddle (7D)
- $0.98
- P/C Volume
- 0.00
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
- Beta (1Y vs SPY)
- 1.06
- Correlation (SPY)
- 29.2%
- R²
- 0.08
- Ann. Volatility
- 47.1%
- SPY Volatility
- 13.0%
Above average volatility - stock moves with market amplification
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $4.12M | 52.38% | 2026-06-30 |
| 2 | MILLENNIUM MANAGEMENT LLC Custodian | $1.47M | 18.65% | 2026-06-30 |
| 3 | CITADEL ADVISORS LLC Custodian | $1.14M | 14.55% | 2026-06-30 |
| 4 | JANE STREET GROUP, LLC Custodian | $1.01M | 12.89% | 2026-06-30 |
| 5 | WOLVERINE TRADING, LLC Custodian | $120.05K | 1.53% | 2025-09-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC Custodian | $1.39M | 53.46% | 2026-06-30 |
| 2 | SUSQUEHANNA INTERNATIONAL GROUP, LLP Custodian | $646.14K | 24.80% | 2026-06-30 |
| 3 | JANE STREET GROUP, LLC Custodian | $465.02K | 17.85% | 2026-06-30 |
| 4 | WOLVERINE TRADING, LLC Custodian | $101.50K | 3.90% | 2025-09-30 |
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-09-21 | WILLIAM P SCULLY | 10%+ Owner | Buy (P) | +100,000 | $8.43 | $843.5K | EDGAR |
| 2026-09-03 | WILLIAM P SCULLY | 10%+ Owner | Buy (P) | +27,000 | $9.47 | $255.7K | EDGAR |
| 2026-08-21 | WILLIAM P SCULLY | 10%+ Owner | Buy (P) | +50,000 | $8.79 | $439.4K | EDGAR |
| 2026-08-18 | WILLIAM P SCULLY | 10%+ Owner | Gift (G) | −291,553 | — | EDGAR | |
| 2026-08-11 | WILLIAM P SCULLY | 10%+ Owner | Gift (G) | +251,553 | — | EDGAR | |
| 2026-08-10 | WILLIAM P SCULLY | 10%+ Owner | Buy (P) | +37,500 | $8.62 | $323.2K | EDGAR |
| 2026-07-30 | Anne Evans Kingston | Chief Strategy Officer | Mixed | −11,160 | $8.50 | -$94.9K | EDGAR |
| 2026-07-30 | Karin L Walker | Chief Accounting Officer | Mixed | — | $8.56 | -$128.4K | EDGAR |
| 2026-07-30 | Tran Nguyen | Chief Strategy Officer and CFO | Mixed | — | $8.56 | -$487.9K | EDGAR |
| 2026-07-30 | Brandon S. Smith | Chief Operating Officer | Mixed | — | $8.56 | -$667.7K | EDGAR |
| 2026-07-30 | Michael John Isaacs | General Counsel & Company Sec. | Mixed | −13,080 | $8.50 | -$111.2K | EDGAR |
| 2026-07-30 | Chad J. Swanson | Chief Development Officer | Mixed | +6,733 | $8.56 | -$378.9K | EDGAR |
| 2026-07-30 | Wagner M. Zago | Chief Scientific Officer | Mixed | — | $8.56 | -$436.6K | EDGAR |
| 2026-07-30 | Gene G. Kinney | President and CEO | Mixed | — | $8.56 | -$719.0K | EDGAR |
| 2026-06-18 | WILLIAM P SCULLY | 10%+ Owner | Buy (P) | +20,000 | $7.90 | $158.0K | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | EcoR1 Capital, LLC | 10%+ Owner | 8,266,342 | $68.53M | -$5.40M | 10 | 2025-05-06 |
| 2 | WILLIAM P SCULLY | 10%+ Owner | 1,010,500 | $8.38M | $7.71M | 13 | 2026-09-21 |
| 3 | Tran Nguyen | Chief Strategy Officer and CFO | 97,205 | $805.8K | -$15.19M | 31 | 2026-07-30 |
| 4 | Wagner M. Zago | Chief Scientific Officer | 85,000 | $704.6K | -$7.97M | 20 | 2026-07-30 |
| 5 | Michael J Malecek | Chief Legal Officer | 80,000 | $663.2K | -$9.34M | 21 | 2026-03-05 |
| 6 | Gene G. Kinney | President and CEO | 68,793 | $570.3K | -$12.41M | 34 | 2026-07-30 |
| 7 | Anne Evans Kingston | Chief Strategy Officer | 55,782 | $462.4K | -$64.9K | 2 | 2026-07-30 |
| 8 | Brandon S. Smith | Chief Operating Officer | 52,000 | $431.1K | -$1.31M | 15 | 2026-07-30 |
| 9 | Dale B. Schenk | President and CEO | 42,910 | $355.7K | -$3.72M | 8 | 2016-02-26 |
| 10 | Chad J. Swanson | Chief Development Officer | 40,733 | $337.7K | $0 | 5 | 2026-07-30 |
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. Amendments (Form 144/A) and post-cancellation refilings can inflate this if you sum naively; the rollup above excludes filings with zero stated value.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-07-29 | ANNE KINGSTON | Officer | 7,662 | $64.9K | 2026-07-29 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-29 | MICHAEL JOHN ISAACS | Officer | 8,386 | $71.1K | 2026-07-29 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-06-09 | MALECEK MICHAEL J | Previous Officer | 80,000 | $740.0K | 2026-06-09 | ETRADE FINANCIAL CORPORATION | — | EDGAR |
| 2024-01-24 | Walker Karin L | Officer | 5,000 | $170.0K | 2024-01-24 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2023-12-20 | Walker Karin L | Officer | 5,000 | $186.4K | 2023-12-20 | UBS Financial Services, Inc | 10b5-1 | EDGAR |
| 2023-11-30 | Walker Karin L | Officer | 5,000 | $170.0K | 2023-11-30 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2023-10-25 | Walker Karin L | Officer | 5,000 | $206.3K | 2023-10-25 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2023-10-11 | Smith Brandon S. | Officer | 4,000 | $189.2K | 2023-10-11 | UBS Financial Services, Inc. | 10b5-1 | EDGAR |
| 2023-10-04 | Karp Carol D. | Officer | 5,000 | $237.0K | 2023-10-04 | UBS Financial Services, Inc | 10b5-1 | EDGAR |
| 2023-09-27 | Malecek Michael J | Officer | 5,000 | $241.1K | 2023-09-27 | UBS Financial Services Inc. | 10b5-1 | EDGAR |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
| P/B Ratio | 1.5 |
| P/S Ratio | 7.8 |
| EV/EBITDA | -2.4 |
| TTM Revenue | $0.1B |
| TTM Net Income | $-0.0B |
| TTM EPS | $-0.84 |
| ROE | -15.3% |